Loading
NASDAQHealthcareBiotechnology
Latest quote
$22.82
−$0.13 · -0.57%
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Latest quote
$22.82
−$0.13 · -0.57%
After-hours
$22.82
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Day range
Current $22.82
52-week range
Current $22.82
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
78
Undervalued
Sentiment
70
Bullish
Risk
60
Elevated Risk
Momentum
43
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Day range
Current $22.82
52-week range
Current $22.82
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 72.3M USD | 28.52M USD | 7.16M USD | — | 6.25M USD |
| Cost of goods sold | 129K USD | 55.93M USD | 48.9M USD | 69.08M USD | — |
| Gross profit | 72.17M USD | −27.41M USD | −41.74M USD | −69.08M USD | 6.25M USD |
| Research and development | 64.81M USD | 55.93M USD | 48.9M USD | 69.98M USD | 68.52M USD |
| Selling, general, and administrative | 19.61M USD | 18.01M USD | 22.91M USD | 23.93M USD | 28.78M USD |
| Operating expenses | 84.42M USD | 18.01M USD | 22.91M USD | 25.03M USD | 138.94M USD |
| Interest income | 6M USD | 5.57M USD | 3.45M USD | 1.02M USD | 302K USD |
| Depreciation and amortization | 129K USD | 129K USD | 450K USD | 498K USD | 466K USD |
| Operating income | −12.12M USD | −45.42M USD | −64.65M USD | −94.11M USD | −132.69M USD |
| Net income | −6.12M USD | −40.18M USD | −61.23M USD | −93.09M USD | −129.86M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$51.67
126.42% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 12, 2024 | 1:12 | — | — |
Stock split | Jul 14, 2014 | 1:5 | — | — |
Effective Feb 12, 2024
1:12
Effective Jul 14, 2014
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI13.9M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM7.93M0.01%78.56B USD0.19%$277.57-0.05%
State Street SPDR S&P Biotech ETFXBI7.12M0.07%10.08B USD0.35%$149.29-0.63%
Vanguard Extended Market ETFVXF4.44M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO1.9M0.01%18B USD0.06%$112.1-0.10%
Vanguard Health Care ETFVHT1.12M0.01%22B USD0.09%$313.85-0.46%
iShares Micro-Cap ETFIWC959.65K0.07%1.33B USD0.60%$182.79-0.31%
Fidelity Enhanced Small Cap ETFFESM522.09K0.01%6.41B USD0.28%$45.25+0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
